Automated screening platform for assessing genetic risk in newborns
CompanyRevvity, Inc., Waltham, USA
To optimize newborn screening, PerkinElmer has developed the high-throughput platform GSP® instrument. The platform enables screening for seven relevant genetic diseases: congenital hypothyroidism, phenylketonuria, galactosemia, cystic fibrosis, congenital adrenal hyperplasia, biotinidase deficiency and glucose-6-phosphate dehydrogenase (G6PD) deficiency. To assess genetic disease risk, the system examines dried blood spot (DBS) samples that are uploaded to the GSP system along with barcoded reagents. After uploading the plates and reagents, the automated system takes over all critical work steps, which are monitored using integrated screening software (Specimen Gate®). Using a touchscreen, researchers can, for example, have their work lists automatically created by a punching device, determine the order of plate analysis or induce new test runs if the results are unclear. In addition, the software includes a quality control program that enables effective and long-term management of patient data. In summary, the GSP instrument platform proves to be an innovative solution that simplifies newborn screening for researchers through automated work steps, at the same time reducing sources of human error and thereby generating precise results more quickly.
GSP® Instrument. Fully automated newborn screening.
www.revvity.com
Added on: 01-11-2024
[1] https://rh.perkinelmer.com/products/gsp-instrument/
